Aspirin and dipyridamole effect on primary patency of arteriovenous grafts
Phase 4
Completed
- Conditions
- Hemodialysis access graft failureAspirin,Dipyridamole,Primary patency,Arteriovenous grafts
- Registration Number
- TCTR20160920003
- Lead Sponsor
- Dr Hasan Ravari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
ESRD patients who underwent placement of a new brachial arteriovenous graft have been included.
Exclusion Criteria
The exclusion criteria was patient younger than 18 years old, pregnancy and all comorbidities that the use of antiplatelet medication was contraindicated
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary patency time 2 weeks after access creation and evrey 1 month Periodic dialysis access physical examination and well done dialysis
- Secondary Outcome Measures
Name Time Method Presence of a palpable thrill in created access 2 weeks after access creation and evrey 1 month Periodic dialysis access physical examination